This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is LL-37?
LL-37 is the only cathelicidin-derived antimicrobial peptide (AMP) found in humans. It is a 37-amino acid peptide cleaved from its precursor protein hCAP-18 (human cationic antimicrobial protein 18 kDa) by the protease proteinase 3. The name "LL-37" refers to its 37 amino acid length and the two leucine residues at its N-terminus. It is produced by epithelial cells, neutrophils, macrophages, and other immune cells, and is found in wound fluid, airway surface liquid, sweat, saliva, and breast milk.
LL-37 is a critical component of the innate immune system — the body's first line of defense against pathogens. Beyond its direct antimicrobial activity, it serves as a multifunctional immune signaling molecule, making it one of the most studied host defense peptides in biomedical research.
Mechanism of Action
LL-37 operates through multiple mechanisms that span direct antimicrobial killing and immune modulation:
- Membrane disruption: As a cationic (positively charged) amphipathic peptide, LL-37 binds to the negatively charged membranes of bacteria, forming pores or disrupting membrane integrity through the "carpet model" mechanism. This electrostatic selectivity means LL-37 targets bacterial membranes (rich in negatively charged phospholipids) while showing much lower affinity for mammalian cell membranes (rich in neutral phospholipids and cholesterol).
- Biofilm disruption: LL-37 is one of the few antimicrobial agents effective against bacterial biofilms — the structured communities that protect bacteria from conventional antibiotics. It disrupts biofilm formation and can penetrate established biofilms at sub-inhibitory concentrations.
- Broad-spectrum activity: Effective against Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses. Activity has been demonstrated against MRSA, Pseudomonas aeruginosa, Candida species, and influenza virus.
- Immune signaling: Acts as a chemoattractant for neutrophils, monocytes, and T-cells via the formyl peptide receptor-like 1 (FPRL1). Promotes angiogenesis and wound healing through direct effects on endothelial cells. Modulates Toll-like receptor signaling, influencing the downstream inflammatory response.
- LPS neutralization: Binds and neutralizes lipopolysaccharide (LPS/endotoxin), potentially reducing the inflammatory cascade triggered by Gram-negative bacterial infections and endotoxemia.
Research Applications
LL-37 research spans multiple therapeutic areas. In wound healing, LL-37 promotes re-epithelialization and angiogenesis — studies show it accelerates wound closure in both in vitro scratch assays and animal wound models. Vitamin D regulation of LL-37 expression has been proposed as a mechanism linking vitamin D deficiency to increased infection susceptibility, and this connection has driven interest in vitamin D supplementation as an indirect way to boost LL-37 levels.
In the context of antibiotic resistance, LL-37 and its derivatives are being explored as novel antimicrobial agents. Because LL-37 kills bacteria through membrane disruption rather than targeting specific metabolic pathways, resistance development is theoretically slower than for conventional antibiotics. Synthetic LL-37 analogs with improved stability and potency are in development for topical and systemic applications.
Dosing and Practical Considerations
- Subcutaneous: 50-100 mcg per day in common research protocols
- Topical: Applied in compounded solutions for wound and skin applications
- Indirect enhancement: Maintaining adequate vitamin D levels (50-70 ng/mL 25-OH-D) supports endogenous LL-37 production
Stability is a consideration with LL-37, as it is susceptible to proteolytic degradation in physiological environments. Research is ongoing into more stable derivatives and delivery systems.
The Bottom Line
LL-37 is the human body's primary antimicrobial peptide, with a remarkably broad range of activities spanning direct pathogen killing, biofilm disruption, immune modulation, and wound healing. Its role in innate immunity is well-established in basic science, and its potential as a therapeutic agent — particularly for antibiotic-resistant infections and chronic wounds — is an active area of translational research. Synthetic LL-37 is available as a research peptide but has not yet reached clinical approval for any indication.